Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia
NCT07513038Phase 2Recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in biliary atresia, sponsored by Boston Children's Hospital. Primary endpoint: Indocyanine green (ICG) fluorescence in stool at 24 hours. Started Aug 2024; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NCT07513038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513038.